SE500494C2 - Pharmaceutical, water-soluble composition containing N-acetyl-cysteine and aspartame - Google Patents
Pharmaceutical, water-soluble composition containing N-acetyl-cysteine and aspartameInfo
- Publication number
- SE500494C2 SE500494C2 SE8702940A SE8702940A SE500494C2 SE 500494 C2 SE500494 C2 SE 500494C2 SE 8702940 A SE8702940 A SE 8702940A SE 8702940 A SE8702940 A SE 8702940A SE 500494 C2 SE500494 C2 SE 500494C2
- Authority
- SE
- Sweden
- Prior art keywords
- weight
- aspartame
- pharmaceutical composition
- composition according
- citric acid
- Prior art date
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title claims abstract description 34
- 108010011485 Aspartame Proteins 0.000 title claims abstract description 24
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 title claims abstract description 24
- 229960003438 aspartame Drugs 0.000 title claims abstract description 24
- 235000010357 aspartame Nutrition 0.000 title claims abstract description 24
- 239000000605 aspartame Substances 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 229960004308 acetylcysteine Drugs 0.000 title claims abstract description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 66
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 28
- 239000008187 granular material Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 14
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims description 10
- 239000007938 effervescent tablet Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- SLHBOSYMAFYMCD-VWMHFEHESA-N CC(=O)N[C@@H](CS)C(O)=O.OC(=O)CC(O)(CC(O)=O)C(O)=O Chemical compound CC(=O)N[C@@H](CS)C(O)=O.OC(=O)CC(O)(CC(O)=O)C(O)=O SLHBOSYMAFYMCD-VWMHFEHESA-N 0.000 claims 4
- 239000005454 flavour additive Substances 0.000 claims 4
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 230000001013 cariogenic effect Effects 0.000 abstract 1
- 230000000510 mucolytic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 7
- 235000011194 food seasoning agent Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 244000248349 Citrus limon Species 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- -1 aluminum-polyethylene Chemical group 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 241000207199 Citrus Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
Abstract
Description
10 15 20 25 30 2 medlet är lämpligt för beredning av den önskade farma- ceutiska formen och är kompatibelt med de därmed för- knippade operationerna. 10 15 20 25 30 2 the agent is suitable for the preparation of the desired pharmaceutical the pharmaceutical form and is compatible with the bundled operations.
En farmaceutisk komposition som innehåller NAC 100% i form av vattenlösliga granulat, som av totalt inbegriper (uttryckt i vikt%): 6-32 vikt% N-acetylcystein 35-50 vikt% citronsyra 26-37 vikt% NaHCO3 1- 1,5 vikt% aspartam 5- 7 vikt% smaktillsats och som har ett viktförhållande mellan citronsyra och NaHCO3 mellan 1,2 och 1,4, har nu påträffats och utgör ändamålet med föreliggande uppfinning.A pharmaceutical composition containing NAC 100% in the form of water-soluble granules, as of total includes (expressed in% by weight): 6-32% by weight of N-acetylcysteine 35-50% by weight of citric acid 26-37% by weight of NaHCO3 1- 1.5% by weight of aspartame 5- 7% by weight of flavoring and which has a weight ratio of citric acid and NaHCO3 between 1.2 and 1.4, have now been found and constitutes the object of the present invention.
De högre värdena för NAC motsvarar de lägre värdena för citronsyra och natriumvätekarbonat.The higher values for NAC correspond to the lower values for citric acid and sodium bicarbonate.
Om det är önskvärt kan citronsyra också användas i form av ett salt, t ex natriumcitrat.If desired, citric acid can also be used in the form of a salt, eg sodium citrate.
Kompositionerna enligt föreliggande uppfinning duger till beredning av farmaceutiska former, såsom brusgranulat eller -tabletter. Båda de resulterande farmaceutiska formerna är lättlösliga i vatten.The compositions of the present invention suitable for the preparation of pharmaceutical forms, such as soda granules or tablets. Both the resulting The pharmaceutical forms are readily soluble in water.
Med tanke på konsumentens acceptabilitet av läke- medlet kan användning av en smaktillsats kräva närvaro av ett färgämne som normalt är förknippat med en sär- skild smak. T ex kan användning av en mintsmaktillsats kräva tillsättning av ett färgämne som ger lösningen grön färg.In view of the consumer's acceptability of the agent, the use of a flavoring may require presence of a dye normally associated with a specific different taste. For example, the use of a mint flavor additive require the addition of a dye that provides the solution green color.
I sådana fall kan det vara användbart att kombinera kompositionen med en mängd färgämne för farmaceutisk användning, t ex i en mängd mellan 0,5 och 1,0 vikt%.In such cases, it may be useful to combine the composition with an amount of dye for pharmaceutical use, for example in an amount between 0.5 and 1.0% by weight.
Exempel på kompositioner enligt föreliggande uppfinning anges i följande tabell. 3 Tabell: Vattenlösliga bruskompositioner A B C D E (mg) (%) (mg)(%) (mg)(%) (mg) (%) (mg) (%) NAC 100 10 200 20 100 6,67 150 10 200 13,33 citronsyra 470 47 412 41,2 738 49,20 708 47,20 680 45,34 NaHCO 345 34,5 303 30,3 542 36,13 522 34,80 500 33,33 aspartam 15 1,5 15 1,5 20 1,33 20 1,33 20 1,33 smaktillsats 70 7 70 7 100 6,67 100 6,67 100 6,67 totalt 1000 100 1000 100 1500 100 1500 100 1500 100 F G (H19) (%) (mg) (%) NAC 400 23,53 600 31,58 citronsyra 680 40,00 680 35,79 NaHCO 500 29,41 500 26,32 aspartam 20 1,18 20 1,05 smaktillsats 100 5,88 100 5,26 totalt 1700 100 1900 100 Bland smaktillsatserna är det föredraget att använda citronsmaktillsats, där den resulterande lösningens färg lätt förknippas med citronsmaken.Examples of compositions according to the present invention invention is set forth in the following table. 3 Table: Water-soluble noise compositions A B C D E (mg) (%) (mg) (%) (mg) (%) (mg) (%) (mg) (%) NAC 100 10 200 20 100 6.67 150 10 200 13.33 citric acid 470 47 412 41.2 738 49.20 708 47.20 680 45.34 NaHCO 345 34.5 303 30.3 542 36.13 522 34.80 500 33.33 aspartame 15 1.5 15 1.5 20 1.33 20 1.33 20 1.33 flavoring 70 7 70 7 100 6.67 100 6.67 100 6.67 total 1000 100 1000 100 1500 100 1500 100 1500 100 F G (H19) (%) (mg) (%) NAC 400 23.53 600 31.58 citric acid 680 40.00 680 35.79 NaHCO 500 29.41 500 26.32 aspartame 20 1.18 20 1.05 flavoring 100 5.88 100 5.26 a total of 1700 100 1900 100 Among the seasonings, it is preferred to use lemon flavor additive, where the resulting solution color is easily associated with the lemon flavor.
Alternativt är det möjligt att använda andra 5 smaktillsatser, såsom t ex apelsinsmaktillsats, som emellertid företrädesvis kombineras med ett lämpligt orange färgämne, t ex B-karoten.Alternatively, it is possible to use others 5 flavorings, such as orange flavoring, which however, preferably combined with a suitable one orange dye, eg B-carotene.
Med hjälp av vid farmaceutiska operationer vanliga förfaranden framställdes de ovan angivna kompositionerna 10 i form av brusgranulat eller -tabletter. Före för- packning utsätts brustabletterna för uppvärmning under en tidsperiod som bestäms som en funktion av tablet- ternas vikt.Using in pharmaceutical operations common procedures, the above compositions were prepared 10 in the form of soda granules or tablets. Before packing, the effervescent tablets are exposed to heating during a period of time determined as a function of the tablet weight.
Granulatet fördelas i lämpliga småpåsar, av vilka 15 var och en innehåller 1-2 g av kompositionen.The granules are distributed in suitable small bags, of which Each contains 1-2 g of the composition.
Alternativt framställs tabletter med en vikt 1,2, Om det är önskvärt kan för preparat med hög NAC- av 1, 1,5, 1,7 eller 1,9 g vardera. halt (t ex 600 mg per dos) större brustabletter med 10 15 20 25 30 35 4 upp till 3 g innehåll eller småpåsar med upp till 3 g innehåll framställas (exempel 5).Alternatively, tablets with a weight are prepared 1.2, If desired, for preparations with high NAC of 1, 1.5, 1.7 or 1.9 g each. content (eg 600 mg per dose) larger effervescent tablets with 10 15 20 25 30 35 4 up to 3 g contents or small bags of up to 3 g content is prepared (Example 5).
Ett typiskt exempel för en sådan komposition är följande: Komposition H (m9) (%) NAC 600 20 citronsyra 1211 40,36 NaHCO3 1009 33,64 aspartam 30 1 citrusfruktsmaktillsats 150 5 totalt 3000 100 Både brusgranulaten och -tabletterna enligt upp- finningen upplöses snabbt i vatten, och ger den vatten- haltiga NAC-lösningen en angenäm smak.A typical example of such a composition is following: Composition H (m9) (%) NAC 600 20 citric acid 1211 40.36 NaHCO 3 1009 33.64 aspartame 30 1 Citrus Flavor Additive 150 5 a total of 3000 100 Both the effervescent granules and tablets according to the solution dissolves rapidly in water, giving it aqueous containing the NAC solution a pleasant taste.
I syfte att förklara föreliggande uppfinning mer detaljerat, men utan att begränsa den, anges nedan följande exempel.In order to explain the present invention more detailed, but without limiting it, is given below the following example.
Exempel l Granulat bestående av 20 kg NAC 41,2 kg citronsyra 30,3 kg NaHCO3 1,5 kg aspartam 7 kg citronsmaktillsats framställdes med hjälp av följande förfarande.Example 1 Granules consisting of 20 kg NAC 41.2 kg of citric acid 30.3 kg NaHCO3 1.5 kg of aspartame 7 kg lemon flavoring was prepared by the following procedure.
NAC och citronsyra siktades genom en sikt med en maskvidd av 1,07 mm och blandades efter tillsättning av aspartam.NAC and citric acid were sieved through a sieve with a mesh size of 1.07 mm and mixed after addition of aspartame.
Blandningen granulerades med vatten i en granulator i form av en fluidiserad bädd.The mixture was granulated with water in a granulator in the form of a fluidized bed.
Natriumvätekarbonat och torkad smaktillsats sattes till de erhållna granulaten och blandades in i dessa.Sodium bicarbonate and dried seasoning were added to the obtained granules and mixed into them.
Blandningen förpackades i småpåsar på ett laminerat aluminium-polyetenark i enkeldoser av 1 g. 10 15 20 25 30 35 mn ti ch 0» 5 Alternativt kan alikvoter av l g av blandningen komprimeras till tabletter och fördelas i småpåsarna i stället.The mixture was packed in small bags on a laminate aluminum-polyethylene sheets in single doses of 1 g. 10 15 20 25 30 35 mn ti ch 0 » 5 Alternatively, aliquots of 1 g of the mixture compressed into tablets and distributed in the small bags instead.
Exempel 2 Granulat bestående av 60 kg NAC 68 kg citronsyra 50 kg NaHCO3 2 kg aspartam 10 kg apelsinsmaktillsats framställdes med hjälp av följande förfarande.Example 2 Granules consisting of 60 kg NAC 68 kg of citric acid 50 kg NaHCO3 2 kg aspartame 10 kg orange flavoring was prepared by the following procedure.
NAC och citronsyra siktades genom en sikt med en maskvidd av 1,07 mm och blandades efter tillsättning av aspartam.NAC and citric acid were sieved through a sieve with a mesh size of 1.07 mm and mixed after addition of aspartame.
Blandningen granulerades i en granulator i form av en fluidiserad bädd med en vattenhaltig lösning av färgämne EllO.The mixture was granulated in a granulator in a mold of a fluidized bed with an aqueous solution of dye EllO.
Natriumvätekarbonat och torkad smaktillsats sattes till de erhållna granulaten och blandades in i denna.Sodium bicarbonate and dried seasoning were added to the obtained granules and mixed into it.
Portioner av 1,9 g av blandningen komprimerades sedan i cirkulära formar med en diameter av 18 mm för erhållande av brustabletter som vardera innehöll 600 mg NAC. Före förpackning i småpâsar upphettades tabletterna på plåtar i en torkningsugn under 2 h vid 70°C.Aliquots of 1.9 g of the mixture were compressed then in circular molds with a diameter of 18 mm to obtain effervescent tablets each containing 600 mg NAC. Before packaging in small bags was heated the tablets on plates in a drying oven for 2 h at 70 ° C.
Alternativt kan blandningen fördelas i småpâsar på ett laminerat aluminium-polyetenark i enkeldoser av 1,9 g.Alternatively, the mixture can be divided into small bags on a laminated aluminum-polyethylene sheet in single doses of 1.9 g.
Brusgranulat och brustabletter av kompositionerna som motsvarar de som beskrivs i den ovan angivna tabellen framställdes med hjälp av ett analogt förfarande.Effervescent granules and effervescent tablets of the compositions corresponding to those described in the table above was prepared by an analogous procedure.
Exempel 3 Granulat bestående av 40 kg NAC 68 kg citronsyra 50 kg NaHCO3 2 kg aspartam 10 kg citrusfrukttillsats 10 15 20 25 30 6 framställdes enligt det i exempel 1 beskrivna förfaran- det. av 1,7 g i en med formar med diametern 18 mm bestyckad Den torkade blandningen komprimerades i enkeldoser kapselframställningskompressor.Example 3 Granules consisting of 40 kg NAC 68 kg of citric acid 50 kg NaHCO3 2 kg aspartame 10 kg citrus fruit additive 10 15 20 25 30 6 was prepared according to the procedure described in Example 1. the. of 1.7 g in one with molds with a diameter of 18 mm equipped The dried mixture was compressed in single doses capsule manufacturing compressor.
Som alternativ till tabletterna kan dessutom doser av 1,7 g förpackas i småpåsar av laminerat alu- minium-polyetenark.As an alternative to the tablets can also doses of 1.7 g are packed in small bags of laminated aluminum minium polyethylene sheet.
Tabletterna och småpàsarna innehöll vid varje tillfälle 400 mg NAC per enkeldos.The tablets and sachets contained at each occasion 400 mg NAC per single dose.
Exempel 4 Granulat bestående av 10 kg NAC 73,8 kg citronsyra 54,2 kg NaHCO 3 2 kg aspartam 10 kg apelsinsmaktillsats framställdes enligt följande förfarande. NAC, citron- syra och aspartam siktades och blandades i en sikt med maskvidden 1,07 mm.Example 4 Granules consisting of 10 kg NAC 73.8 kg of citric acid 54.2 kg NaHCO 3 2 kg aspartame 10 kg orange flavoring was prepared according to the following procedure. NAC, lemon- acid and aspartame were sieved and mixed in a sieve with mesh size 1.07 mm.
Blandningen granulerades därefter i en vanlig granulator med en vatten-alkohollösning (med ett för- hållande mellan vatten och alkohol av 1:1).The mixture was then granulated in a plain granulator with a water-alcohol solution (with a pre- holding between water and alcohol of 1: 1).
Det på så sätt bildade granulatet torkades i en tork och siktades på en med en sikt med maskvidden 0,9 mm bestyckad svänggranulator.The granules thus formed were dried in a dryer and sieved on one with a sieve with the mesh size 0.9 mm equipped swivel granulator.
Det på så sätt bildade granulatet blandades med natriumvätekarbonat och smaktillsats.The granules thus formed were mixed with sodium bicarbonate and seasoning.
Portioner av 1,5 g av blandningen komprimerades till runda former med en diameter av 15 mm, varvid brustabletter bildades, höll 150 mg NAC. Som alternativ kan brusblandningen som vid varje tillfälle inne- förpackas i småpåsar av laminerat a1uminium-po1yeten- ark i en enkeldos av 3 g, varvid varje liten påse innehåller 300 mg NAC. 10 15 20 Exempel 5 Granulat 30 kg 60,55 kg 50,45 kg NaHCO3 1,5 aspartam 7,5 framställdes enligt följande förfarande. NAC och citron- bestående av NAC citronsyra apelsinsmaktillsats syra siktades på en sikt med maskvidden 1,07 mm och blandades efter tillsättning av aspartam.Aliquots of 1.5 g of the mixture were compressed into round shapes with a diameter of 15 mm, wherein effervescent tablets were formed, held 150 mg NAC. Alternatively, the soda mixture can which at any given time packaged in small bags of laminated aluminum-polyethylene- sheets in a single dose of 3 g, each small bag contains 300 mg NAC. 10 15 20 Example 5 Granules 30 kg 60.55 kg 50.45 kg NaHCO3 1.5 aspartame 7.5 was prepared according to the following procedure. NAC and lemon consisting of NAC citric acid orange flavoring acid was sieved on a 1.07 mm mesh screen and was mixed after the addition of aspartame.
Blandningen granulerades därefter i en vanlig granulator med vatten. Det på så sätt bildade granu- latet torkades i en tork och siktades i en med en sikt med en maskvidd av 0,9 mm bestyckad svänggranu- lator. Det på så sätt bildade granulatet blandades med natriumvätekarbonat och smaktillsats.The mixture was then granulated in a plain granulator with water. The granules thus formed the lathe was dried in a dryer and sieved in one by one sieve with a mesh size of 0,9 mm lator. The granules thus formed were mixed with sodium bicarbonate and seasoning.
Portioner av 3 g av blandningen komprimerades till runda former med en diameter av 25 mm, varigenom brustabletter bildades, som vid varje tillfälle inne- höll 600 mg NAC. också förpackas i småpåsar av laminerat aluminium- Som alternativ kan brusblandningen polyetenark i enkeldoser av 3 g, varvid varje liten påse innehåller 600 mg NAC.Aliquots of 3 g of the mixture were compressed into round shapes with a diameter of 25 mm, whereby effervescent tablets were formed, which in each case contained held 600 mg NAC. also packaged in small bags of laminated aluminum Alternatively, the soda mixture can polyethylene sheets in single doses of 3 g, each small bag contains 600 mg NAC.
Claims (16)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2975/86A CH667590A5 (en) | 1986-07-24 | 1986-07-24 | WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8702940D0 SE8702940D0 (en) | 1987-07-23 |
| SE8702940L SE8702940L (en) | 1988-01-25 |
| SE500494C2 true SE500494C2 (en) | 1994-07-04 |
Family
ID=4245841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8702940A SE500494C2 (en) | 1986-07-24 | 1987-07-23 | Pharmaceutical, water-soluble composition containing N-acetyl-cysteine and aspartame |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE1000355A3 (en) |
| CH (1) | CH667590A5 (en) |
| DE (1) | DE3723735A1 (en) |
| FR (1) | FR2601876B1 (en) |
| GB (1) | GB2192790B (en) |
| IT (1) | IT1222104B (en) |
| NL (1) | NL194067C (en) |
| SE (1) | SE500494C2 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1217445B (en) * | 1988-04-29 | 1990-03-22 | Altergon Sa | SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING ACETYLCISTEIN |
| DE3822096A1 (en) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | STABILIZED DRUG PREPARATION |
| SE462779B (en) * | 1988-10-10 | 1990-09-03 | Lejus Medical Ab | PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL CYSTEIN IN A CERNA COATED WITH HYDROXIPROPYLMETHYL CELLULOS AGREEMENT |
| DE3909049A1 (en) * | 1989-03-18 | 1990-09-20 | Arthur Boskamp | PREPARATION AND THEIR USE |
| IT1231012B (en) * | 1989-07-27 | 1991-11-08 | Zambon Spa | PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING NAC. |
| DK0497724T3 (en) * | 1991-01-26 | 1996-04-29 | Senju Pharma Co | Means for the disintegration of gallstones |
| DE4103360A1 (en) * | 1991-02-05 | 1992-08-06 | Koehler Peter | Use of acetyl-cysteine and isotonic sodium chloride (0.9 per cent) - for treating bronchial asthma and bronchitis-induced spasms |
| US5296500A (en) * | 1991-08-30 | 1994-03-22 | The Procter & Gamble Company | Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy |
| IT1256616B (en) * | 1992-12-02 | 1995-12-12 | Zambon Spa | SYRUP CONTAINING N-ACETYL-CISTEIN |
| DE4406261C2 (en) * | 1993-08-31 | 1996-07-04 | Deutsches Krebsforsch | Use of thiol compounds to reduce body fat |
| BE1007926A3 (en) * | 1994-01-31 | 1995-11-21 | Zambon Int Pharma | Pharmaceutical composition containing n-acetyl-cysteine. |
| US5451405A (en) * | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
| DE19509856C2 (en) * | 1995-03-17 | 1997-09-11 | Schwabe Willmar Gmbh & Co | Use of an effervescent composition with Ginkgo biloba dry extract for the treatment of peripheral and cerebral circulatory disorders |
| WO2000018392A1 (en) * | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
| EP1115842A4 (en) | 1998-09-25 | 2002-08-21 | Glycox Corp Ltd | Fructosamine oxidase assay: methods and materials |
| ES2386782T3 (en) | 2002-03-08 | 2012-08-30 | Philera New Zealand Limited | Prevention and / or treatment of cardiovascular disease and / or associated heart failure |
| MXPA05002883A (en) | 2002-08-20 | 2005-10-05 | Protemix Corp Ltd | Dosage forms and related therapies. |
| AU2005281353A1 (en) | 2004-07-19 | 2006-03-16 | Philera New Zealand Limited | Synthesis of triethylenetetramines |
| TR200900882A2 (en) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Pharmaceutical compositions with high bioavailability, masked by taste and odor. |
| TR200900881A2 (en) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Stable pharmaceutical compositions masked by taste and odor |
| IT1399492B1 (en) | 2010-04-13 | 2013-04-19 | Alpex Pharma Sa | EFFERVESCENT PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYLCISTEIN. |
| CN102233139B (en) * | 2010-04-21 | 2012-09-05 | 重庆健能医药开发有限公司 | Acetylcysteine effervescent tablet and preparation method and application thereof |
| WO2011146031A1 (en) * | 2010-05-18 | 2011-11-24 | Bilgic Mahmut | Pharmaceutical composition comprising n- acetylcysteine and a xanthine |
| CN101947211A (en) * | 2010-08-28 | 2011-01-19 | 浙江金华康恩贝生物制药有限公司 | Method for preparing acetylcysteine effervescent tablet |
| TR201104738A2 (en) * | 2011-05-16 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Pharmaceutical combination containing N-Acetylcysteine. |
| US8747894B2 (en) * | 2012-05-08 | 2014-06-10 | Alpex Pharma S.A. | Effervescent compositions containing N-acetylcysteine |
| EP2905020A1 (en) | 2014-02-05 | 2015-08-12 | Sanovel Ilac Sanayi ve Ticaret A.S. | Effervescent formulations comprising ibuprofen and N-acetylcystein |
| CN113559078A (en) * | 2021-07-02 | 2021-10-29 | 安徽省先锋制药有限公司 | Preparation method of acetylcysteine effervescent tablets |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2470M (en) * | 1962-03-13 | 1964-04-20 | Mead Johnson & Co | Therapeutic composition. |
| ZA723683B (en) * | 1971-07-12 | 1973-06-27 | Hoffmann La Roche | Improved effervescent preparations |
| DE3317558A1 (en) * | 1983-05-13 | 1984-11-15 | Dietrich Dr.med. Sta. Eulalia Ibiza Reichert | Oral antisnoring composition |
| DE3317530A1 (en) * | 1983-05-13 | 1984-11-15 | Dietrich Dr.med. Sta. Eulalia Ibiza Reichert | Antisnoring composition |
| IT1170268B (en) * | 1983-12-21 | 1987-06-03 | Zambon Spa | USE OF ACETYLCISTEIN TO REDUCE THE INCREASE IN THE PROLIEFERATION OF THE BASAL CELLS OF THE RESPIRATORY THRACHEO-BRONCHIAL EPITHELIUM INDUCED BY TOBACCO SMOKE IN MAMMALS |
| DE3514995A1 (en) * | 1985-04-25 | 1986-10-30 | Protopharma Ltd., 7831 Malterdingen | Use of sulfhydryl pharmaceuticals for combating damage to the gastric mucosa |
-
1986
- 1986-07-24 CH CH2975/86A patent/CH667590A5/en not_active IP Right Cessation
-
1987
- 1987-07-17 DE DE19873723735 patent/DE3723735A1/en active Granted
- 1987-07-22 FR FR878710368A patent/FR2601876B1/en not_active Expired
- 1987-07-23 SE SE8702940A patent/SE500494C2/en not_active IP Right Cessation
- 1987-07-23 NL NL8701743A patent/NL194067C/en not_active IP Right Cessation
- 1987-07-23 BE BE8700816A patent/BE1000355A3/en not_active IP Right Cessation
- 1987-07-23 IT IT21411/87A patent/IT1222104B/en active
- 1987-07-27 GB GB8717582A patent/GB2192790B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2601876B1 (en) | 1989-10-13 |
| SE8702940L (en) | 1988-01-25 |
| IT8721411A0 (en) | 1987-07-23 |
| NL194067C (en) | 2001-06-05 |
| FR2601876A1 (en) | 1988-01-29 |
| GB8717582D0 (en) | 1987-09-03 |
| CH667590A5 (en) | 1988-10-31 |
| IT1222104B (en) | 1990-08-31 |
| DE3723735A1 (en) | 1988-02-04 |
| BE1000355A3 (en) | 1988-11-08 |
| SE8702940D0 (en) | 1987-07-23 |
| NL194067B (en) | 2001-02-01 |
| DE3723735C2 (en) | 1992-05-21 |
| NL8701743A (en) | 1988-02-16 |
| GB2192790B (en) | 1990-01-31 |
| GB2192790A (en) | 1988-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE500494C2 (en) | Pharmaceutical, water-soluble composition containing N-acetyl-cysteine and aspartame | |
| SE500493C2 (en) | Pharmaceutical, water-soluble composition containing N-acetyl-cysteine, aspartame and sorbitol | |
| US4806358A (en) | Therapeutic compositions | |
| RU2417034C2 (en) | Packed solid concentrated products for preparation of broth, soup, sauce, sauce seasoning or dressing or for application as condiment, their production method and application | |
| SE502285C2 (en) | Effervescent pharmaceutical composition containing ranitidine, and process for its preparation | |
| BRPI0719623A2 (en) | '' Processes for Producing a Concentrate in the Form of Particles for Preparing Broth, Soups, Sauces, Bouillon or for Use as a Seasoning, For Preparing a Broth or Concentrate in a Form of Cube or Tray, Concentrated in the Form of Particles TO PREPARE BRUSH, SOUP, SAUCE, MEAT OR FOR USE AS SEASONING AND USE OF CONCENTRATE '' | |
| JPS5645159A (en) | Preparation of foamable chewing gum | |
| JP2011153147A (en) | Soft capsule film and soft capsule | |
| ES2632416T3 (en) | Consomed tablet process | |
| JPS6061517A (en) | Compression molded tablet | |
| JP2009518029A (en) | Instant food containing flavor capsules | |
| JP6702494B2 (en) | Solid | |
| US4113865A (en) | Fruit juice-sugar granules | |
| EP1949795A1 (en) | Seasoning | |
| JPS6192530A (en) | Health drink | |
| JP4865905B1 (en) | Deodorant composition | |
| JP4722077B2 (en) | Yakudon Udon and Yakudon Udon Set | |
| JPH02211848A (en) | Functional food containing protein polysaccharide component of agaricus blazei | |
| JP2019201630A (en) | Solid material | |
| JP5615522B2 (en) | Solid pharmaceutical composition | |
| KR980000114A (en) | Recipe of Green Tea Noodles | |
| JP3983011B2 (en) | Manufacturing method for fish cutting | |
| CN110800975A (en) | Chicken essence for chicken essence production and blending method thereof | |
| AU6391294A (en) | Palatable low salt substitutes | |
| JPH04152868A (en) | Preparation of powder or granule of sale cake and processed food prepared by using powder or granule of sake cake |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |